Adlai Nortye Ltd.
ANLHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Adlai Nortye Ltd. focuses on Biotechnology services and products. Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. With a market capitalization of $742.5M, it sits in small-cap territory. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rectal cancer.
Market Cap
$742.5M
Beta
1.11
P/E (TTM)
—
P/E (Fwd)
-30.83
EPS (TTM)
$-1.13
EPS (Fwd)
$-0.37
ROE
-414.0%
ROA
-42.2%
Cash
$9.0M
Total Debt
$26.4M
Free CF
-$37.7M
52W Change
668.7%
Annual Financials
Cash vs Debt
Adlai Nortye Ltd. carries $26.4M in total debt against $9.0M in cash reserves — debt is roughly 2.9x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$37.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -414.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Adlai Nortye Ltd.'s trajectory.